Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01389596 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
A Phase 3 study of Epilepsy, Partial Seizures, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 295
- Enrollment target
- 20
- Study locations
NCT01389596 is a Phase 3 study of Epilepsy, Partial Seizures that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 295 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT01389596, a Phase 3 study of Epilepsy, Partial Seizures, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 295 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study A0081041 is a double blind, placebo controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of two dose levels of pregabalin administered in equally divided daily doses, in either capsule or oral liquid formulation, as adjunctive therapy in pediatric subjects 4 to 16 years of age with partial onset seizures.
Conditions Studied
Interventions
- DRUG Pregabalin add-on therapy
Study Locations (20)
Kentucky
- Center for Clinical and Translational Science - Lexington
- Kentucky Neuroscience Institute - Lexington
- University of Kentucky Hospital Epilepsy Monitoring Unit - Lexington
- University of Kentucky Hospital Pharmacy, UK Chandler Hosptial - Lexington
- Kosair Charities Pediatric Clinical - Louisville
- Kosair Children's Hospital - Louisville
- University of Louisville Physicians - Louisville
Florida
- Axcess Medical Research - Loxahatchee Groves
- Laszlo J. Mate, M.D., P.A. - North Palm Beach
- Pediatric Neurology, P.A. - Orlando
- Tallahassee Neurological Clinic - Tallahassee
California
- Children's Hospital Los Angeles - Los Angeles
- Children´s Hospital Los Angeles - Los Angeles
North Carolina
- Duke Children's Hospital and Health Center - Durham
- Duke Clinical Research Unit - Durham
Arizona
- Center for Neurosciences - Tucson
Arkansas
- Arkansas Children's Hospital - Little Rock
New Jersey
- Saint Peter's University Hospital - New Brunswick
Ohio
- Akron Children's Hospital - Akron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2011-09-27 |
| Est. Completion | 2016-08-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01389596
The ClinicalTrials.gov registry entry for NCT01389596 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy, Partial Seizures appearing as the primary indexed condition, and to 1 intervention - of which Pregabalin add-on therapy is the first listed.
NCT01389596 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Kentucky, Florida, California.
Frequently Asked Questions
What is clinical trial NCT01389596 about?
NCT01389596 is a clinical study titled "A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years". Study A0081041 is a double blind, placebo controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of two dose levels of pregabalin administered in equally divided daily doses, in either capsule or oral liquid formulation, as adjunctive therapy in pediatric subje...
What is the current status of trial NCT01389596?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 295 participants. The study started on 2011-09-27. Estimated completion is 2016-08-10.
What conditions does trial NCT01389596 study?
This clinical trial studies the following conditions: Epilepsy, Partial Seizures.
What interventions are being tested in trial NCT01389596?
The interventions under investigation include: Pregabalin add-on therapy (DRUG).
Who is sponsoring clinical trial NCT01389596?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01389596 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy, Partial Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.